Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Attendance
Registration fees
Hotel
Venue
Eco-friendly info
Programme
Abstract Submission
Postgraduate Teaching
Nurse Programme
Hands-on
Industry Programme
Acknowledgements
CME Accreditation
UEG Week on-demand
Congress Resources
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Projects
Research Prize
Research Fellowship
Research Webinars
Advocacy
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
Guideline development framework
Guideline development course
Get Funding
Get Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Application Support
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Author
Axel Dignass
EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
Axel Dignass
et al.
EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Axel Dignass
et al.
IN CONTRAST TO ORAL IRON THERAPY, INTRAVENOUS IRON THERAPY IS NEITHER INFLUENCED BY, NOR DOES IT EXACERBATE, SYSTEMIC INFLAMMATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Axel Dignass
et al.
IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Axel Dignass
et al.
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
Axel Dignass
et al.
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
Axel Dignass
et al.
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
Axel Dignass
et al.
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
Axel Dignass
et al.
A GLOBAL CONSENSUS ON THE DEFINITIONS, DIAGNOSIS AND MANAGEMENT OF FIBROSTENOSING SMALL BOWEL CROHN'S DISEASE
Axel Dignass
et al.
HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS
Axel Dignass
et al.
CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE
Axel Dignass
et al.
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Axel Dignass
et al.
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS AT WEEK 12 BY PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO ADVANCED THERAPY
Axel Dignass
et al.
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Axel Dignass
et al.
THE EFFICACY OF INDUCTION TREATMENT WITH GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12 BY PRIOR ADVANCED THERAPY HISTORY
Axel Dignass
et al.
European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease
Axel Dignass
et al.
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
Axel Dignass
et al.
European evidence based consensus on surgery for ulcerative colitis
Axel Dignass
et al.
Item 21 - 38 / 38
1
2
Chat with us
, powered by
LiveChat